The Healthy Aging Company is a privately
owned biopharmaceutical company with a dual presence in France and the United States, dedicated to transforming the landscape of age-related disease treatment.
Focuses on developing first-in-class drug candidates that target Type 2 Diabetes Mellitus (T2DM) and its complications, striving to redefine patient care and disease management.
THAC is a resident at The Institute of Diabetes,
Paris (France)
and at the University of South Florida (US)
At the forefront of innovation, THAC is spearheading a revolutionary approach to tackling T2DM, neuropathy, and Alzheimer’s disease by targeting insulin resistance, the root cause of these debilitating conditions. Our drug candidates leverage a unique mechanism of action to combat oxidation and inflammation while directly modulating the gut microbiome, unlocking unprecedented potential for improved patient outcomes.
This transformative therapy offers the promise of:
Enhanced
glycemic
control
Prevention of severe complications, such as peripheral neuropathy, diabetic foot wounds, and amputations
Mitigation of cognitive decline associated with Alzheimer’s disease
Lorem ipsum dolor sit amet, consectetur adipiscing eli.